Skip to main content
. 2017 Feb 8;10:32. doi: 10.3389/fnmol.2017.00032

Figure 4.

Figure 4

BMP9 treatment attenuated tau phosphorylation in APP/PS1 mice. (A) Brain sections of the cortex and hippocampus were stained with anti-phospho-tau (ser202, Thr205; AT-8). (B) The proportions of AT-8-positive area were calculated. Bar = 100 μm. (C) Representative western blots of phosphorylated tau at residues T181, S356, S396, and S199, as well as those of total tau and GAPDH in the hippocampus homogenates from APP/PS1 mice treated with vehicle or BMP9. (D) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. (E) Representative western blots of pGSK3α, GSK3α, pGSK3β, GSK3β, cyclin-dependent kinase 5 (CDK5), PP2A-C, pPP2A-C (Y307), demethylated PP2A-C (D-PP2A-C), PP2A-B and GAPDH in the hippocampus homogenates from APP/PS1 mice treated with vehicle or BMP9. (F) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. Values are represented as the mean ± SD. Student’s t test or ANOVA followed by Bonferroni’s post hoc test. *p < 0.05, n = 6.